Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002807 · ClinicalTrials.gov registry record · Phase 1
Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01002807 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 15 participants.
The verdict
NCT01002807, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
To assess the relative bioavailability of dapagliflozin and metformin from the two FDC formulations, comprised of 10 mg dapagliflozin and 1000 mg metformin XR, relative to coadministration of a dapagliflozin 10 mg tablet and 2 x 500 mg Glucophage® XR tablets, in healthy subjects in a fasted state.
Interventions
- DRUG Dapagliflozin
- DRUG Metformin XR
- DRUG Glucophage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01002807
The ClinicalTrials.gov registry entry for NCT01002807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dapagliflozin is the first listed.
NCT01002807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01002807 about?
NCT01002807 is a clinical study titled "Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State". To assess the relative bioavailability of dapagliflozin and metformin from the two FDC formulations, comprised of 10 mg dapagliflozin and 1000 mg metformin XR, relative to coadministration of a dapagliflozin 10 mg tablet and 2 x 500 mg Glucophage® XR tablets, in healthy subjects in a fasted state.
What is the current status of trial NCT01002807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2009-11. Estimated completion is 2010-01.
What interventions are being tested in trial NCT01002807?
The interventions under investigation include: Dapagliflozin (DRUG), Metformin XR (DRUG), Glucophage (DRUG).
Who is sponsoring clinical trial NCT01002807?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.